-+ 0.00%
-+ 0.00%
-+ 0.00%

Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT)

Barchart·07/30/2026 16:34:00
Listen to the news

Phathom Pharmaceuticals guided FY 2026 revenue as high as $345 million while building out a sales force of more than 290 representatives. The revised outlook now tops out at $325 million, and PHAT shareholders absorbed the decline.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.